epa11017891 The Vertex Pharmaceuticals headquarters in Boston, Massachusetts, USA, 08 December 2023. The US Food and Drug Administration approved Casgevy, jointly developed by Vertex Pharmaceuticals and CRISPR Therapeutics of Switzerland, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. EPA/CJ GUNTHER
